Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Venrock Healthcare Capital Par Buys 8,971 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 8,971 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was bought at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the completion of the purchase, the insider now directly owns 4,044,684 shares of the company's stock, valued at $47,969,952.24. The trade was a 0.22 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 14th, Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock. The stock was purchased at an average cost of $11.44 per share, with a total value of $1,015,803.36.
• On Monday, February 10th, Venrock Healthcare Capital Par acquired 574 shares of Oruka Therapeutics stock. The stock was purchased at an average price of $10.90 per share, for a total transaction of $6,256.60.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock traded down $0.12 during trading on Monday, reaching $10.04. The company's stock had a trading volume of 140,217 shares, compared to its average volume of 285,565. The stock has a fifty day moving average price of $14.29. Oruka Therapeutics, Inc. has a one year low of $9.53 and a one year high of $53.88. The company has a market cap of $351.21 million, a price-to-earnings ratio of -1.60 and a beta of 0.77.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $6,787,000. Toronto Dominion Bank acquired a new position in Oruka Therapeutics during the 4th quarter valued at $1,131,000. Frazier Life Sciences Management L.P. boosted its holdings in Oruka Therapeutics by 22.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 583,327 shares of the company's stock valued at $11,311,000 after purchasing an additional 106,000 shares during the period. VR Adviser LLC grew its position in Oruka Therapeutics by 6.5% in the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock worth $63,708,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth about $236,000. 56.44% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ORKA has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.